Am Fam Physician. 2010 Sep 15;82(6):577-583.
Vitamin D Supplementation in Patients with Tuberculosis
Original Article: Recognition and Management of Vitamin D Deficiency
Issue Date: October 15, 2009
Available at: http://www.aafp.org/afp/2009/1015/p841.html
to the editor: Dr. Bordelon and colleagues provide a timely and useful summary of the management of vitamin D deficiency. However, they cite tuberculosis as a contraindication to vitamin D supplementation, which is not the case. Activated macrophages produce elevated amounts of 1-α-hydroxylase, which can potentially produce toxic levels of 1,25-dihydroxyvitamin D if adequate substrate 25-hydroxyvitamin D is available; therefore, there are concerns about the risk of hypercalcemia in patients with tuberculosis or other granulomatous diseases.
In 1984, Narang and colleagues reported high rates of hypercalcemia in patients with or without tuberculosis receiving vitamin D supplementation,1 forming the basis of these concerns. However, these results have not been reproduced and are speculated to have stemmed from underestimating the actual amount of vitamin D administered in the study.2
More recent data show that vitamin D supplementation in patients with tuberculosis does not appear to be associated with hypercalcemia. In preliminary safety data from one study, 11 patients with tuberculosis were administered a single dose of 100,000 IU ergocalciferol (vitamin D2).3 At eight weeks, there was a significant rise in serum vitamin D2 levels and no episodes of hypercalcemia. In a randomized trial of 100,000 IU cholecalciferol (vitamin D3) in patients with tuberculosis in Guinea-Bissau,4 t here was no difference in hypercalcemia symptoms or detection of biochemical hypercalcemia in those randomized to the treatment arm; however, patients in the treatment arm did not attain higher serum vitamin D levels than those randomized to placebo, suggesting that the vitamin D formulation used (an injectable preparation given orally) may have been poorly absorbed. Other studies, summarized elsewhere,5,6 have also reported safe administration of vitamin D in patients with tuberculosis.
Given the evidence of the potential benefits of vitamin D3 in the immune response to Mycobacterium tuberculosis, 6 optimizing vitamin D levels (while monitoring calcium levels) should not be considered contraindicated in patients with tuberculosis. Results from trials of vitamin D adjunctive therapy that are currently underway will provide further clarification of the benefit, if any, of vitamin D supplementation in patients with tuberculosis.
1. Narang NK, Gupta RC, Jain MK. Role of vitamin D in pulmonary tuberculosis. J Assoc Physicians India. 1984;32(2):185–188.
2. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr. 2001;73(2):288–294.
3. Martineau AR, Nanzer AM, Satkunam KR, et al. Influence of a single oral dose of vitamin D(2) on serum 25-hydroxyvitamin D concentrations in tuberculosis patients. Int J Tuberc Lung Dis. 2009;13(1):119–125.
4. Wejse C, Gomes VF, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2009;179(9):843–850.
5. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol. 2007;103(3–5):793–798.
6. Ralph AP, Kelly PM, Anstey NM. L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis. Trends Microbiol. 2008;16(7):336–344.
editor's note: This letter was sent to the authors of "Recognition and Management of Vitamin D Deficiency," who declined to reply.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions